{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:39:18Z","timestamp":1787891958529,"version":"build-2784847793"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["5F31CA224536-02"],"award-info":[{"award-number":["5F31CA224536-02"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["DP1CA216873"],"award-info":[{"award-number":["DP1CA216873"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"DOI":"10.13039\/100000051","name":"U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute","doi-asserted-by":"publisher","award":["UM1HG009390"],"award-info":[{"award-number":["UM1HG009390"]}],"id":[{"id":"10.13039\/100000051","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chromatin regulators are frequently mutated in human cancer and are attractive drug targets. They include diverse proteins that share functional domains and assemble into related multi-subunit complexes. To investigate functional relationships among these regulators, here we apply combinatorial CRISPR knockouts (KOs) to test over 35,000 gene-gene pairings in leukemia cells, using a library of over 300,000 constructs. Top pairs that demonstrate either compensatory non-lethal interactions or synergistic lethality enrich for paralogs and targets that occupy the same protein complex. The screen highlights protein complex dependencies not apparent in single KO screens, for example MCM histone exchange, the nucleosome remodeling and deacetylase (NuRD) complex, and HBO1 (KAT7) complex. We explore two approaches to NuRD complex inactivation. Paralog and non-paralog combinations of the KAT7 complex emerge as synergistic lethal\u00a0and specifically nominate the ING5 PHD domain as a potential therapeutic target when paired with other KAT7 complex member losses. These findings highlight the power of combinatorial screening to provide mechanistic insight and identify therapeutic targets within redundant networks.<\/jats:p>","DOI":"10.1038\/s41467-023-36150-7","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T08:03:50Z","timestamp":1674806630000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Chromatin complex dependencies reveal targeting opportunities in leukemia"],"prefix":"10.1038","volume":"14","author":[{"given":"Fadi J.","family":"Najm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4707-7940","authenticated-orcid":false,"given":"Peter","family":"DeWeirdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7833-0769","authenticated-orcid":false,"given":"Molly M.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha M.","family":"Bevill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9374-103X","authenticated-orcid":false,"given":"Chadi A.","family":"El Farran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin A.","family":"Macias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mudra","family":"Hegde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda L.","family":"Waterbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2985-462X","authenticated-orcid":false,"given":"Brian B.","family":"Liau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0735-1570","authenticated-orcid":false,"given":"Peter","family":"van Galen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3707-9889","authenticated-orcid":false,"given":"John G.","family":"Doench","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5726-6278","authenticated-orcid":false,"given":"Bradley E.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,27]]},"reference":[{"key":"36150_CR1","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nrg.2016.59","volume":"17","author":"CD Allis","year":"2016","unstructured":"Allis, C. D. & Jenuwein, T. The molecular hallmarks of epigenetic control. Nat. Rev. Genet. 17, 487\u2013500 (2016).","journal-title":"Nat. Rev. Genet."},{"key":"36150_CR2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nature14248","volume":"518","author":"Roadmap Epigenomics Consortium.","year":"2015","unstructured":"Roadmap Epigenomics Consortium. et al. Integrative analysis of 111 reference human epigenomes. Nature 518, 317\u2013330 (2015).","journal-title":"Nature"},{"key":"36150_CR3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.tig.2015.10.007","volume":"32","author":"M Lawrence","year":"2016","unstructured":"Lawrence, M., Daujat, S. & Schneider, R. Lateral thinking: how histone modifications regulate gene expression. Trends Genet. 32, 42\u201356 (2016).","journal-title":"Trends Genet."},{"key":"36150_CR4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41586-019-1182-7","volume":"569","author":"R Stadhouders","year":"2019","unstructured":"Stadhouders, R., Filion, G. J. & Graf, T. Transcription factors and 3D genome conformation in cell-fate decisions. Nature 569, 345\u2013354 (2019).","journal-title":"Nature"},{"key":"36150_CR5","doi-asserted-by":"publisher","first-page":"eaal2380","DOI":"10.1126\/science.aal2380","volume":"357","author":"WA Flavahan","year":"2017","unstructured":"Flavahan, W. A., Gaskell, E. & Bernstein, B. E. Epigenetic plasticity and the hallmarks of cancer. Science 357, eaal2380 (2017).","journal-title":"Science"},{"key":"36150_CR6","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1101\/gad.255182.114","volume":"29","author":"MA Morgan","year":"2015","unstructured":"Morgan, M. A. & Shilatifard, A. Chromatin signatures of cancer. Genes Dev. 29, 238\u2013249 (2015).","journal-title":"Genes Dev."},{"key":"36150_CR7","doi-asserted-by":"publisher","first-page":"a040956","DOI":"10.1101\/cshperspect.a040956","volume":"14","author":"B Gryder","year":"2021","unstructured":"Gryder, B., Scacheri, P. C., Ried, T. & Khan, J. Chromatin mechanisms driving cancer. Cold Spring Harb. Perspect. Biol. 14, a040956 (2021).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"36150_CR8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nbt.4048","volume":"36","author":"FJ Najm","year":"2017","unstructured":"Najm, F. J. et al. Orthologous CRISPR\u2013Cas9 enzymes for combinatorial genetic screens. Nat. Biotechnol. 36, 179\u2013189 (2017).","journal-title":"Nat. Biotechnol."},{"key":"36150_CR9","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nbt.3834","volume":"35","author":"K Han","year":"2017","unstructured":"Han, K. et al. Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions. Nat. Biotechnol. 35, 463\u2013474 (2017).","journal-title":"Nat. Biotechnol."},{"key":"36150_CR10","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41587-020-0470-y","volume":"38","author":"JM Replogle","year":"2020","unstructured":"Replogle, J. M. et al. Combinatorial single-cell CRISPR screens by direct guide RNA capture and targeted sequencing. Nat. Biotechnol. 38, 954\u2013961 (2020).","journal-title":"Nat. Biotechnol."},{"key":"36150_CR11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41587-020-0600-6","volume":"39","author":"PC DeWeirdt","year":"2021","unstructured":"DeWeirdt, P. C. et al. Optimization of AsCas12a for combinatorial genetic screens in human cells. Nat. Biotechnol. 39, 94\u2013104 (2021).","journal-title":"Nat. Biotechnol."},{"key":"36150_CR12","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1038\/s41588-021-00967-z","volume":"53","author":"T Ito","year":"2021","unstructured":"Ito, T. et al. Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers. Nat. Genet. 53, 1664\u20131672 (2021).","journal-title":"Nat. Genet."},{"key":"36150_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-020-02173-2","volume":"21","author":"M Dede","year":"2020","unstructured":"Dede, M., McLaughlin, M., Kim, E. & Hart, T. Multiplex enCas12a screens detect functional buffering among paralogs otherwise masked in monogenic Cas9 knockout screens. Genome Biol. 21, 262 (2020).","journal-title":"Genome Biol."},{"key":"36150_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21478-9","volume":"12","author":"NA Thompson","year":"2021","unstructured":"Thompson, N. A. et al. Combinatorial CRISPR screen identifies fitness effects of gene paralogues. Nat. Commun. 12, 1302 (2021).","journal-title":"Nat. Commun."},{"key":"36150_CR15","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41587-020-0437-z","volume":"38","author":"T Gonatopoulos-Pournatzis","year":"2020","unstructured":"Gonatopoulos-Pournatzis, T. et al. Genetic interaction mapping and exon-resolution functional genomics with a hybrid Cas9-Cas12a platform. Nat. Biotechnol. 38, 638\u2013648 (2020).","journal-title":"Nat. Biotechnol."},{"key":"36150_CR16","doi-asserted-by":"publisher","unstructured":"Esmaeili Anvar, N. et al. Combined genome-scale fitness and paralog synthetic lethality screens with just 44k clones: the IN4MER CRISPR\/Cas12a multiplex knockout platform. bioRxiv (2023) https:\/\/doi.org\/10.1101\/2023.01.03.522655.","DOI":"10.1101\/2023.01.03.522655"},{"key":"36150_CR17","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nbt.3235","volume":"33","author":"J Shi","year":"2015","unstructured":"Shi, J. et al. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nat. Biotechnol. 33, 661\u2013667 (2015).","journal-title":"Nat. Biotechnol."},{"key":"36150_CR18","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak, A. et al. Defining a cancer dependency map. Cell 170, 564\u2013576.e16 (2017).","journal-title":"Cell"},{"key":"36150_CR19","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.cell.2015.11.015","volume":"163","author":"T Hart","year":"2015","unstructured":"Hart, T. et al. High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell 163, 1515\u20131526 (2015).","journal-title":"Cell"},{"key":"36150_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26867-8","volume":"12","author":"WF Lenoir","year":"2021","unstructured":"Lenoir, W. F. et al. Discovery of putative tumor suppressors from CRISPR screens reveals rewired lipid metabolism in acute myeloid leukemia cells. Nat. Commun. 12, 6506 (2021).","journal-title":"Nat. Commun."},{"key":"36150_CR21","doi-asserted-by":"publisher","first-page":"e1008466","DOI":"10.1371\/journal.pgen.1008466","volume":"15","author":"B De Kegel","year":"2019","unstructured":"De Kegel, B. & Ryan, C. J. Paralog buffering contributes to the variable essentiality of genes in cancer cell lines. PLoS Genet. 15, e1008466 (2019).","journal-title":"PLoS Genet."},{"key":"36150_CR22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/nature01198","volume":"421","author":"Z Gu","year":"2003","unstructured":"Gu, Z. et al. Role of duplicate genes in genetic robustness against null mutations. Nature 421, 63\u201366 (2003).","journal-title":"Nature"},{"key":"36150_CR23","doi-asserted-by":"publisher","first-page":"109597","DOI":"10.1016\/j.celrep.2021.109597","volume":"36","author":"PCR Parrish","year":"2021","unstructured":"Parrish, P. C. R. et al. Discovery of synthetic lethal and tumor suppressor paralog pairs in the human genome. Cell Rep. 36, 109597 (2021).","journal-title":"Cell Rep."},{"key":"36150_CR24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/nar\/gkw813","volume":"45","author":"J Ibn-Salem","year":"2017","unstructured":"Ibn-Salem, J., Muro, E. M. & Andrade-Navarro, M. A. Co-regulation of paralog genes in the three-dimensional chromatin architecture. Nucleic Acids Res. 45, 81\u201391 (2017).","journal-title":"Nucleic Acids Res."},{"key":"36150_CR25","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1093\/molbev\/mst086","volume":"30","author":"F Abascal","year":"2013","unstructured":"Abascal, F. et al. Subfunctionalization via adaptive evolution influenced by genomic context: the case of histone chaperones ASF1a and ASF1b. Mol. Biol. Evol. 30, 1853\u20131866 (2013).","journal-title":"Mol. Biol. Evol."},{"key":"36150_CR26","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41586-019-1835-6","volume":"577","author":"L MacPherson","year":"2020","unstructured":"MacPherson, L. et al. HBO1 is required for the maintenance of leukaemia stem cells. Nature 577, 266\u2013270 (2020).","journal-title":"Nature"},{"key":"36150_CR27","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1038\/s41375-020-1001-z","volume":"35","author":"YZ Au","year":"2021","unstructured":"Au, Y. Z. et al. KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements. Leukemia 35, 1012\u20131022 (2021).","journal-title":"Leukemia"},{"key":"36150_CR28","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nm.3480","volume":"20","author":"KC Helming","year":"2014","unstructured":"Helming, K. C. et al. ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat. Med. 20, 251\u2013254 (2014).","journal-title":"Nat. Med."},{"key":"36150_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1158\/2159-8290.CD-12-0361","volume":"3","author":"JN Wu","year":"2013","unstructured":"Wu, J. N. & Roberts, C. W. M. ARID1A mutations in cancer: another epigenetic tumor suppressor? Cancer Discov. 3, 35\u201343 (2013).","journal-title":"Cancer Discov."},{"key":"36150_CR30","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/nrc3091","volume":"11","author":"AY Lai","year":"2011","unstructured":"Lai, A. Y. & Wade, P. A. Cancer biology and NuRD: a multifaceted chromatin remodelling complex. Nat. Rev. Cancer 11, 588\u2013596 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"36150_CR31","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.molcel.2018.06.003","volume":"71","author":"S Bornel\u00f6v","year":"2018","unstructured":"Bornel\u00f6v, S. et al. The nucleosome remodeling and deacetylation complex modulates chromatin structure at sites of active transcription to fine-tune gene expression. Mol. Cell 71, 56\u201372.e4 (2018).","journal-title":"Mol. Cell"},{"key":"36150_CR32","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1038\/s41588-019-0453-4","volume":"51","author":"F Sher","year":"2019","unstructured":"Sher, F. et al. Rational targeting of a NuRD subcomplex guided by comprehensive in situ mutagenesis. Nat. Genet. 51, 1149\u20131159 (2019).","journal-title":"Nat. Genet."},{"key":"36150_CR33","doi-asserted-by":"publisher","first-page":"e100788","DOI":"10.15252\/embj.2018100788","volume":"38","author":"T Burgold","year":"2019","unstructured":"Burgold, T. et al. The nucleosome remodelling and deacetylation complex suppresses transcriptional noise during lineage commitment. EMBO J. 38, e100788 (2019).","journal-title":"EMBO J."},{"key":"36150_CR34","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1182\/blood.2021014461","volume":"139","author":"FJ Najm","year":"2022","unstructured":"Najm, F. J. & van Galen, P. Renewing your HBO1 subscription. Blood 139, 802\u2013804 (2022).","journal-title":"Blood"},{"key":"36150_CR35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.molcel.2005.12.007","volume":"21","author":"Y Doyon","year":"2006","unstructured":"Doyon, Y. et al. ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. Mol. Cell 21, 51\u201364 (2006).","journal-title":"Mol. Cell"},{"key":"36150_CR36","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/j.jmb.2019.04.018","volume":"431","author":"G Ormaza","year":"2019","unstructured":"Ormaza, G. et al. The tumor suppressor ING5 is a dimeric, bivalent recognition molecule of the histone H3K4me3 Mark. J. Mol. Biol. 431, 2298\u20132319 (2019).","journal-title":"J. Mol. Biol."},{"key":"36150_CR37","doi-asserted-by":"publisher","first-page":"e65872","DOI":"10.7554\/eLife.65872","volume":"10","author":"S Takahashi","year":"2021","unstructured":"Takahashi, S. et al. HBO1-MLL interaction promotes AF4\/ENL\/P-TEFb-mediated leukemogenesis. Elife 10, e65872 (2021).","journal-title":"Elife"},{"key":"36150_CR38","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41589-021-00920-5","volume":"18","author":"AR Conery","year":"2022","unstructured":"Conery, A. R., Rocnik, J. L. & Trojer, P. Small molecule targeting of chromatin writers in cancer. Nat. Chem. Biol. 18, 124\u2013133 (2022).","journal-title":"Nat. Chem. Biol."},{"key":"36150_CR39","doi-asserted-by":"publisher","first-page":"e19760","DOI":"10.7554\/eLife.19760","volume":"5","author":"MA Horlbeck","year":"2016","unstructured":"Horlbeck, M. A. et al. Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation. Elife 5, e19760 (2016).","journal-title":"Elife"},{"key":"36150_CR40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"36150_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"36150_CR42","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nmeth.3885","volume":"13","author":"N Ignatiadis","year":"2016","unstructured":"Ignatiadis, N., Klaus, B., Zaugg, J. B. & Huber, W. Data-driven hypothesis weighting increases detection power in genome-scale multiple testing. Nat. Methods 13, 577\u2013580 (2016).","journal-title":"Nat. Methods"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-36150-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-36150-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-36150-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T23:35:26Z","timestamp":1674948926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-36150-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,27]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["36150"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-36150-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,27]]},"assertion":[{"value":"19 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.E.B. declares outside interests in Fulcrum Therapeutics, HiFiBio, Arsenal Biosciences, Cell Signaling Technologies, Chroma Medicine, and Design Pharmaceuticals. J.G.D. consults for Microsoft Research, Abata Therapeutics, Servier, Maze Therapeutics, BioNTech, Sangamo, and Pfizer. J.G.D. consults for and has equity in Tango Therapeutics. J.G.D. serves as a paid scientific advisor to the Laboratory for Genomics Research, funded in part by GlaxoSmithKline. J.G.D. receives funding support from the Functional Genomics Consortium: Abbvie, Bristol Myers Squibb, Janssen, Merck, and Vir Biotechnology. J.G.D.\u2019s interests were reviewed and are managed by the Broad Institute in accordance with its conflict of interest policies. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"448"}}